Evidence for GLP-1 Therapy in MASH

Panelists discuss how GLP-1 receptor agonists, originally developed for diabetes and obesity, are demonstrating significant hepatic benefits in clinical trials. They review evidence from multiple studies showing improved liver histology, reduced steatosis, and potential reversal of inflammation and fibrosis.

They explain how these agents’ metabolic effects—weight loss, improved insulin sensitivity, and reduced inflammation—translate into hepatoprotective outcomes, positioning GLP-1 therapies as a cornerstone of future MASH treatment.

Panelists note the importance of adapting existing obesity treatment frameworks to accommodate liver-specific indications, emphasizing coordinated guideline updates and provider education.